| Age (years) [median (range)] |
52 (29–74) |
| Sex |
|
|
Male [n (%)] |
105 (63.6%) |
|
Female [n (%)] |
60 (36.4%) |
| Body mass index (kg/m2) [median (range)] |
24.6 (18.4–48.4) |
|
IFNL4 genotype |
|
|
CC [n (%)] |
46 (29.1%) |
|
non-CC [n (%)] |
112 (70.9%) |
|
n.d. [n] |
7 |
| Liver enyzmes |
|
|
ALT (U/l) [median (range)] |
86 (19–551) |
|
AST (U/l) [median (range)] |
65 (5–301) |
|
GGT [median (range)] |
82 (12–508) |
| Cirrhosis |
|
|
Patients with cirrhosis [n (%)] |
47 (28.5%) |
|
Patients without cirrhosis [n (%)] |
118 (71.5%) |
| Fibrosis |
|
|
F0-F2 [n (%)] |
40 (42.1%) |
|
F3-F4 [n (%)] |
55 (57.9%) |
|
n.d. [n] |
70 |
| HCV infection |
|
|
HCV viral load (IU/mL) [median (range)] |
1.6x106 (3.6x103–3.6x107) |
|
HCV GT 1a [n (%)] |
74 (44.8%) |
|
HCV GT 1b [n (%)] |
91 (55.2%) |
| Current Treatment |
|
|
BOC-based [n (%)] |
29 (17.6%) |
|
TVR-based [n (%)] |
136 (82.4%) |
| Outcome |
|
|
SVR [n (%)] |
121 (73.3%) |
|
Virologic Failure [n (%)] |
44 (26.7) |
|
|
Non-Response [n (% virologic failure)] |
14 (31.8%) |
|
|
Breakthrough [n (% virologic failure)] |
12 (27.3%) |
|
|
Relapse [n (% virologic failure)] |
18 (40.9%) |
| Treatment History |
|
|
Treatment-naïve [n (%)] |
60 (36.8%) |
|
Treatment-experienced ((PEG)-IFN +/- RBV) [n (%)] |
103 (63.2%) |
|
n.d. [n] |
2 |
| HIV Coinfection |
|
|
Patients with HIV infection [n (%)] |
11 (7.9%) |
|
Patients with HIV <20 copies/mL [n% HIV infected)] |
10 (90.9%) |
|
HIV status n.d. |
26 |
| HBV Coinfection |
|
|
Patients with HBV infection [n (%)] |
2 (1.4%) |
|
Patients with HBV <20 copies/mL [n% HBV infected)] |
2 (100%) |
|
HBV status n.d. |
26 |
